Strategic Financial Services Inc. Sells 412 Shares of Johnson & Johnson $JNJ

Strategic Financial Services Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,289 shares of the company’s stock after selling 412 shares during the quarter. Strategic Financial Services Inc.’s holdings in Johnson & Johnson were worth $1,540,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at about $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the first quarter valued at about $49,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $50,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $175.70 on Thursday. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a market capitalization of $423.15 billion, a PE ratio of 18.79, a P/E/G ratio of 2.25 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a 50-day simple moving average of $169.91 and a two-hundred day simple moving average of $161.12.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the firm earned $2.82 earnings per share. The company’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson’s payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Morgan Stanley lifted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. Finally, Barclays boosted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.